Erratum to Dermal delivery of HSP47 siRNA with NOX4-modulating mesoporous silica-based nanoparticles for treating fibrosis [Biomaterials, 66, (2015), 41-52] DOI:10.1016/j.biomaterials.2015.07.005;Dermal delivery of HSP47 siRNA with NOX4-modulating mesoporous silica-based nanoparticles for treating fibrosis

Biomaterials

Volumn 66, Issue , 2015, Pages 41-52

  Morry, Jingga ^a   Ngamcherdtrakul, Worapol ^a   Gu, Shenda ^a   Goodyear, Shaun M ^a   Castro, David J ^a,b   Reda, Moataz M ^a   Sangvanich, Thanapon ^a   Yantasee, Wassana ^a,b  

^a Oregon Health and Science University Department of Biomedical Engineering   (United States)

^b PDX Pharmaceuticals LLC   (United States)

Author keywords

Dermal delivery; Fibrosis; HSP47; MSNP; NOX4; SiRNA

Indexed keywords

AMINO ACIDS; ANTIOXIDANTS; BIOSYNTHESIS; CELL CULTURE; COLLAGEN; MAMMALS;

DERMAL DELIVERY; FIBROSIS; HSP47; MSNP; NOX4; SIRNA;

SILICA NANOPARTICLES;

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; HEAT SHOCK PROTEIN 47; MACROGOL; POLYETHYLENEIMINE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SILICA NANOPARTICLE; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; NANOCAPSULE; NOX4 PROTEIN, MOUSE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SERPINH1 PROTEIN, MOUSE; SILICON DIOXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; DOWN REGULATION; FIBROBLAST; FIBROGENESIS; FIBROSIS; GENE EXPRESSION; GENE SILENCING; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCLERODERMA; SKINFOLD THICKNESS; ANIMAL; C3H MOUSE; CELL SURVIVAL; CHEMISTRY; CUTANEOUS DRUG ADMINISTRATION; DRUG EFFECTS; GENE THERAPY; GENETICS; NANOPORE; PARTICLE SIZE; POROSITY; PROCEDURES; SCLERODERMA, DIFFUSE; TREATMENT OUTCOME; ULTRASTRUCTURE;

MUS;

ADMINISTRATION, CUTANEOUS; ANIMALS; CELL SURVIVAL; GENE SILENCING; GENETIC THERAPY; HSP47 HEAT-SHOCK PROTEINS; MICE; MICE, INBRED C3H; NADPH OXIDASE; NANOCAPSULES; NANOPORES; PARTICLE SIZE; POROSITY; RNA, SMALL INTERFERING; SCLERODERMA, DIFFUSE; SILICON DIOXIDE; TREATMENT OUTCOME;

EID: 84938053018     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.09.028     Document Type: Erratum

References (74)

1. Cheresh P., Kim S.J., Tulasiram S., Kamp D.W. Oxidative stress and pulmonary fibrosis. Biochim. Biophys. Acta 2013, 1832:1028-1040.
2. Gabrielli A., Svegliati S., Moroncini G., Amico D. New insights into the role of oxidative stress in scleroderma fibrosis. Open Rheumatol. J. 2012, 6:87-95.
3. Stramer B.M., Mori R., Martin P. The inflammation-fibrosis link? A Jekyll and Hyde role for blood cells during wound repair. J.Investig. Dermatol. 2007, 127:1009-1017.
4. Bringardner B.D., Baran C.P., Eubank T.D., Marsh C.B. The role of inflammation in the pathogenesis of idiopathic pulmonary fibrosis. Antioxid. Redox Signal. 2008, 10:287-301.
5. Wynn T.A. Integrating mechanisms of pulmonary fibrosis. J.Exp. Med. 2011, 208:1339-1350.
6. Borg B.B., Seetharam A., Subramanian V., Basha H.I., Lisker-Melman M., Korenblat K., et al. Immune response to extracellular matrix collagen in chronic hepatitis C-induced liver fibrosis. Liver Transplant. 2011, 17:814-823.
7. Leask A., Abraham D.J. TGF-beta signaling and the fibrotic response. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2004, 18:816-827.
8. Bitterman P.B., Henke C.A. Fibroproliferative disorders. Chest 1991, 99:81s-84s.
9. Wick G., Grundtman C., Mayerl C., Wimpissinger T.F., Feichtinger J., Zelger B., et al. The immunology of fibrosis. Annu. Rev. Immunol. 2013, 31:107-135.
10. Rafii R., Juarez M.M., Albertson T.E., Chan A.L. Areview of current and novel therapies for idiopathic pulmonary fibrosis. J.Thorac. Dis. 2013, 5:48-73.
11. Buchman A.L. Side effects of corticosteroid therapy. J.Clin. Gastroenterol. 2001, 33:289-294.
12. Flaherty K.R., Toews G.B., Lynch J.P., Kazerooni E.A., Gross B.H., Strawderman R.L., et al. Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival. Am. J. Med. 2001, 110:278-282.
13. Martinez F.J., de Andrade J.A., Anstrom K.J., King T.E., Raghu G. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N.Engl. J. Med. 2014, 370:2093-2101.
14. de la Maza M.P., Petermann M., Bunout D., Hirsch S. Effects of long-term vitamin E supplementation in alcoholic cirrhotics. J.Am. Coll. Nutr. 1995, 14:192-196.
15. Denton C.P., Merkel P.A., Furst D.E., Khanna D., Emery P., Hsu V.M., et al. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum. 2007, 56:323-333.
16. Prey S., Ezzedine K., Doussau A., Grandoulier A.S., Barcat D., Chatelus E., et al. Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial. Br. J. Dermatol. 2012, 167:1138-1144.
17. Saikia J.P., Paul S., Konwar B.K., Samdarshi S.K. Nickel oxide nanoparticles: a novel antioxidant. Colloids Surf. B Biointerfaces 2010, 78:146-148.
18. Nomura M., Yoshimura Y., Kikuiri T., Hasegawa T., Taniguchi Y., Deyama Y., et al. Platinum nanoparticles suppress osteoclastogenesis through scavenging of reactive oxygen species produced in RAW264.7 cells. J.Pharmacol. Sci. 2011, 117:243-252.
19. Onizawa S., Aoshiba K., Kajita M., Miyamoto Y., Nagai A. Platinum nanoparticle antioxidants inhibit pulmonary inflammation in mice exposed to cigarette smoke. Pulm. Pharmacol. Ther. 2009, 22:340-349.
20. Watanabe A., Kajita M., Kim J., Kanayama A., Takahashi K., Mashino T., et al. Invitro free radical scavenging activity of platinum nanoparticles. Nanotechnology 2009, 20:455105-455114.
21. Heckert E.G., Karakoti A.S., Seal S., Self W.T. The role of cerium redox state in the SOD mimetic activity of nanoceria. Biomaterials 2008, 29:2705-2709.
22. Schubert D., Dargusch R., Raitano J., Chan S.W. Cerium and yttrium oxide nanoparticles are neuroprotective. Biochem. Biophys. Res. Commun. 2006, 342:86-91.
23. Hao N., Yang H., Li L., Li L., Tang F. The shape effect of mesoporous silica nanoparticles on intracellular reactive oxygen species in A375 cells. New J. Chem. 2014, 38:4258-4266.
24. Huang X., Zhuang J., Teng X., Li L., Chen D., Yan X., et al. The promotion of human malignant melanoma growth by mesoporous silica nanoparticles through decreased reactive oxygen species. Biomaterials 2010, 31:6142-6153.
25. Shahbazi M.A., Herranz B., Santos H.A. Nanostructured porous Si-based nanoparticles for targeted drug delivery. Biomatter 2012, 2:296-312.
26. Godin B., Gu J., Serda R.E., Ferrati S., Liu X., Chiappini C., et al. Multistage mesoporous silicon-based nanocarriers: biocompatibility with immune cells and controlled degradation in physiological fluids. Control. Release Newsl. Control. Release Soc. 2008, 25:9-11.
27. Asefa T., Tao Z. Biocompatibility of mesoporous silica nanoparticles. Chem. Res. Toxicol. 2012, 25:2265-2284.
28. Bajenaru L., Berger D., Miclea L., Matei C., Nastase S., Andronescu C., et al. Correlation of the intracellular reactive oxygen species levels with textural properties of functionalized mesostructured silica. J.Biomed. Mater. Res. A 2014, 102:4435-4442.
29. Nisimoto Y., Diebold B.A., Cosentino-Gomes D., Lambeth J.D. Nox4: a hydrogen peroxide-generating oxygen sensor. Biochemistry 2014, 53:5111-5120.
30. Jiang J.X., Chen X., Serizawa N., Szyndralewiez C., Page P., Schroder K., et al. Liver fibrosis and hepatocyte apoptosis are attenuated by GKT137831, a novel NOX4/NOX1 inhibitor invivo. Free Radic. Biol. Med. 2012, 53:289-296.
31. Amara N., Goven D., Prost F., Muloway R., Crestani B., Boczkowski J. NOX4/NADPH oxidase expression is increased in pulmonary fibroblasts from patients with idiopathic pulmonary fibrosis and mediates TGFbeta1-induced fibroblast differentiation into myofibroblasts. Thorax 2010, 65:733-738.
32. Hecker L., Vittal R., Jones T., Jagirdar R., Luckhardt T.R., Horowitz J.C., et al. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat. Med. 2009, 15:1077-1081.
33. Piera-Velazquez S., Jimenez S.A. Role of cellular senescence and NOX4-mediated oxidative stress in systemic sclerosis pathogenesis. Curr. Rheumatol. Rep. 2015, 17:473-483.
34. Spadoni T., Svegliati Baroni S., Amico D., Albani L., Moroncini G., Avvedimento E.V., et al. Areactive oxygen species-mediated loop maintains the increased expression of NOX2 and NOX4 in skin fibroblasts from patients with systemic sclerosis. Arthritis Rheumatol. (Hoboken, NJ) 2015, 67:1611-1622.
35. Michaeloudes C., Sukkar M.B., Khorasani N.M., Bhavsar P.K., Chung K.F. TGF-β regulates Nox4, MnSOD and catalase expression, and IL-6 release in airway smooth muscle cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 2011, 300:L295-L304.
36. Dykxhoorn D.M., Palliser D., Lieberman J. The silent treatment: siRNAs as small molecule drugs. Gene Ther. 2006, 13:541-552.
37. Li X., Chen Y., Wang M., Ma Y., Xia W., Gu H. Amesoporous silica nanoparticle-PEI-fusogenic peptide system for siRNA delivery in cancer therapy. Biomaterials 2013, 34:1391-1401.
38. Meng H., Mai W.X., Zhang H., Xue M., Xia T., Lin S., et al. Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer invitro and invivo. ACS Nano 2013, 7:994-1005.
39. Lin D., Cheng Q., Jiang Q., Huang Y., Yang Z., Han S., et al. Intracellular cleavable poly(2-dimethylaminoethyl methacrylate) functionalized mesoporous silica nanoparticles for efficient siRNA delivery invitro and invivo. Nanoscale 2013, 5:4291-4301.
40. Shen J., Kim H.C., Su H., Wang F., Wolfram J., Kirui D., et al. Cyclodextrin and polyethylenimine functionalized mesoporous silica nanoparticles for delivery of siRNA cancer therapeutics. Theranostics 2014, 4:487-497.
41. Ngamcherdtrakul W., Morry J., Gu S., Castro D.J., Goodyear S.M., Sangvanich T., et al. Cationic polymer modified mesoporous silica nanoparticles for targeted siRNA delivery to HER2+ breast cancer. Adv. Funct. Mater. 2015, 25:2646-2659.
42. Ishida Y., Nagata K. Chapter nine - Hsp47 as a collagen-specific molecular chaperone. Methods in Enzymology 2011, 167-182. Academic Press. C.W. James, I.B. Phillip (Eds.).
43. Kuroda K., Tsukifuji R., Shinkai H. Increased expression of heat-shock protein 47 is associated with overproduction of type I procollagen in systemic sclerosis skin fibroblasts. J.Investig. Dermatol. 1998, 111:1023-1028.
44. Naitoh M., Hosokawa N., Kubota H., Tanaka T., Shirane H., Sawada M., et al. Upregulation of HSP47 and collagen type III in the dermal fibrotic disease, keloid. Biochem. Biophys. Res. Commun. 2001, 280:1316-1322.
45. Razzaque M.S., Kumatori A., Harada T., Taguchi T. Coexpression of collagens and collagen-binding heat shock protein 47 in human diabetic nephropathy and IgA nephropathy. Nephron 1998, 80:434-443.
46. Amenomori M., Mukae H., Sakamoto N., Kakugawa T., Hayashi T., Hara A., et al. HSP47 in lung fibroblasts is a predictor of survival in fibrotic nonspecific interstitial pneumonia. Respir. Med. 2010, 104:895-901.
47. Brown K.E., Broadhurst K.A., Mathahs M.M., Brunt E.M., Schmidt W.N. Expression of HSP47, a collagen-specific chaperone, in normal and diseased human liver. Lab. Investig. J. Tech. Methods Pathol. 2005, 85:789-797.
48. Sato Y., Murase K., Kato J., Kobune M., Sato T., Kawano Y., et al. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat. Biotechnol. 2008, 26:431-442.
49. Ishiwatari H., Sato Y., Murase K., Yoneda A., Fujita R., Nishita H., et al. Treatment of pancreatic fibrosis with siRNA against a collagen-specific chaperone in vitamin A-coupled liposomes. Gut 2013, 62:1328-1339.
50. Obata Y., Nishino T., Kushibiki T., Tomoshige R., Xia Z., Miyazaki M., et al. HSP47 siRNA conjugated with cationized gelatin microspheres suppresses peritoneal fibrosis in mice. Acta biomater. 2012, 8:2688-2696.
51. Leachman S.A., Hickerson R.P., Schwartz M.E., Bullough E.E., Hutcherson S.L., Boucher K.M., et al. First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol. Ther. J. Am. Soc. Gene Ther. 2009, 18:442-446.
52. Yamamoto T., Takagawa S., Katayama I., Yamazaki K., Hamazaki Y., Shinkai H., et al. Animal model of sclerotic skin. I: local injections of bleomycin induce sclerotic skin mimicking scleroderma. J.Investig. Dermatol. 1999, 112:456-462.
53. Takashima A. Establishment of fibroblast cultures. Curr. Protoc. Cell Biol. 2001, 2.1-2.1.12. 2008/01/30 ed.
54. Boucherat O., Franco-Montoya M.L., Thibault C., Incitti R., Chailley-Heu B., Delacourt C., et al. Gene expression profiling in lung fibroblasts reveals new players in alveolarization. Physiol. Genomics 2007, 32:128-141.
55. Yamamoto T., Nishioka K. Animal model of sclerotic skin. V: increased expression of alpha-smooth muscle actin in fibroblastic cells in bleomycin-induced scleroderma. Clin. Immunol. 2002, 102:77-83.
56. Brand-Williams W., Cuvelier M.E., Berset C. Use of a free radical method to evaluate antioxidant activity. LWT - Food Sci. Technol. 1995, 28:25-30.
57. Jacobson G.B., Gonzalez-Gonzalez E., Spitler R., Shinde R., Leake D., Kaspar R.L., et al. Biodegradable nanoparticles with sustained release of functional siRNA in skin. J.Pharm. Sci. 2010, 99:4261-4266.
58. Hegde V., Hickerson R.P., Nainamalai S., Campbell P.A., Smith F.J.D., McLean W.H.I., et al. Invivo gene silencing following non-invasive siRNA delivery into the skin using a novel topical formulation. J.Control. Release 2014, 196:355-362.
59. Loor G., Kondapalli J., Schriewer J.M., Chandel N.S., Vanden Hoek T.L., Schumacker P.T. Menadione triggers cell death through ROS-dependent mechanisms involving PARP activation without requiring apoptosis. Free Radic. Biol. Med. 2010, 49:1925-1936.
60. Read M.L., Singh S., Ahmed Z., Stevenson M., Briggs S.S., Oupicky D., et al. Aversatile reducible polycation-based system for efficient delivery of a broad range of nucleic acids. Nucleic Acids Res. 2005, 33:e86. (1-16).
61. Kawakami T., Ihn H., Xu W., Smith E., LeRoy C., Trojanowska M. Increased expression of TGF-beta receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-beta signaling to scleroderma phenotype. J.Investig. Dermatol. 1998, 110:47-51.
62. Sambo P., Baroni S.S., Luchetti M., Paroncini P., Dusi S., Orlandini G., et al. Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis Rheum. 2001, 44:2653-2664.
63. Pohlers D., Brenmoehl J., Loffler I., Muller C.K., Leipner C., Schultze-Mosgau S., et al. TGF-beta and fibrosis in different organs - molecular pathway imprints. Biochim. Biophys. Acta 2009, 1792:746-756.
64. Xu Q., Norman J.T., Shrivastav S., Lucio-Cazana J., Kopp J.B. Invitro models of TGF-beta-induced fibrosis suitable for high-throughput screening of antifibrotic agents. Am. J. Physiol. Ren. Physiol. 2007, 293:F631-F640.
65. Lakos G., Takagawa S., Chen S.-J., Ferreira A.M., Han G., Masuda K., et al. Targeted disruption of TGF-β/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma. Am. J. Pathol. 2004, 165:203-217.
66. Oi M., Yamamoto T., Nishioka K. Increased expression of TGF-beta1 in the sclerotic skin in bleomycin-'susceptible' mouse strains. J.Med. Dent. Sci. 2004, 51:7-17.
67. Hong S.-Y., Gil H.-W., Yang J.-O., Lee E.-Y., Kim H.-K., Kim S.-H., et al. Effect of high-dose intravenous N-acetylcysteine on the concentration of plasma sulfur-containing amino acids. Korean J. Intern. Med. 2005, 20:217-223.
68. Sasaki H., Sato T., Yamauchi N., Okamoto T., Kobayashi D., Iyama S., et al. Induction of heat shock protein 47 synthesis by TGF-β and IL-1β via enhancement of the heat shock element binding activity of heat shock transcription factor 1. J.Immunol. 2002, 168:5178-5183.
69. Chan E.C., Peshavariya H.M., Liu G.-S., Jiang F., Lim S.-Y., Dusting G.J. Nox4 modulates collagen production stimulated by transforming growth factor β1 invivo and invitro. Biochem. Biophys. Res. Commun. 2013, 430:918-925.
70. Jiang F., Liu G.-S., Dusting G.J., Chan E.C. NADPH oxidase-dependent redox signaling in TGF-β-mediated fibrotic responses. Redox Biol. 2014, 2:267-272.
71. Barnes J.L., Gorin Y. Myofibroblast differentiation during fibrosis: role of NAD(P)H oxidases. Kidney Int. 2011, 79:944-956.
72. Yu A.L., Moriniere J., Birke M., Neumann C., Fuchshofer R., Kampik A., et al. Reactivation of optic nerve head astrocytes by TGF-β2 and H2O2 is accompanied by increased Hsp32 and Hsp47 expression. Investig. Ophthalmol. Vis. Sci. 2009, 50:1707-1717.
73. Gosslau A., Ruoff P., Mohsenzadeh S., Hobohm U., Rensing L. Heat shock and oxidative stress-induced exposure of hydrophobic protein domains as common signal in the induction of hsp68. J.Biol. Chem. 2001, 276:1814-1821.
74. Sikic B.I. Biochemical and cellular determinants of bleomycin cytotoxicity. Cancer Surv. 1986, 5:81-91.